medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2015, Número 2

<< Anterior Siguiente >>

Rev Biomed 2015; 26 (2)


Fisiopatología de cálculos biliares de colesterol: la búsqueda de una diana terapéutica

Castro-Torres IG, Bermúdez-Camps IB

Idioma: Español
Referencias bibliográficas: 46
Paginas: 87-97
Archivo PDF: 306.71 Kb.


RESUMEN

En la fisiopatología de los cálculos biliares de colesterol se involucran diferentes desajustes tales como, la alteración en la secreción de lípidos biliares, la cristalización o nucleación del colesterol, la sobreproducción de proteínas mucinas que modifican la motilidad de la vesícula biliar y la alteración en el transporte intestinal de colesterol. En estas fases intervienen numerosas moléculas por ejemplo, los transportadores ABCG5, ABCG8, ABCB11 y ABCB4, los genes MUC que se encargan de expresar las proteínas mucinas, la colecistocinina (CCK) y su receptor tipo 1 y la proteína de Niemann-Pick C1L1 intestinal (NPC1L1). En esta revisión, discutimos los resultados de estudios sobre estas moléculas que tienen una participación específica dentro de la formación de los cálculos biliares de colesterol. La modulación de la expresión de estas proteínas, puede ser una importante pauta de investigación para el hallazgo de una diana terapéutica para la prevención y el tratamiento de esta enfermedad de la vesícula biliar.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Stinton LM & Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 2012 Apr; 6(2): 172-87.

  2. Van Erpecum KJ. Pathogenesis of cholesterol and pigment gallstones: an update. Clin Res Hepatol Gastroenterol. 2011 Apr; 35(4): 281-7.

  3. Chuang SC, Hsi E, Lee KT. Genetics of gallstone disease. Adv Clin Chem. 2013 Jun; 60(5): 143-85.

  4. Castro-Torres IG, De la O-Arciniega M, Bravo-Duarte GA, Gallegos-Estudillo J, Domínguez-Ortíz MA, Martínez-Vázquez M. Intestinal and hepatic Niemann-Pick C1L1 proteins: future therapeutic targets for cholesterol gallstones disease? Eur J Pharmacol. 2014 Apr; 728 (1): 77-81.

  5. Castro-Torres IG. Cholesterol gallstones formation: new scientific advances. Rev GEN. 2012 Jan-Mar; 66(1): 57-62.

  6. Portincasa P & Wang DQ. Intestinal absorption, hepatic synthesis, and biliary secretion of cholesterol: where are we for cholesterol gallstone formation? Hepatology. 2012 May; 55(5): 1313-16.

  7. Dikkers A & Tietge UJ. Biliary cholesterol secretion: more than a simple ABC. World J Gastroenterol. 2010 Dec; 16(47): 5936-45.

  8. Maurer KJ, Carey MC, Fox JG. Roles of infection, inflammation, and the immune system in cholesterol gallstone formation. Gastroenterology. 2009 Feb; 136(2): 425-40.

  9. Smelt AH. Triglycerides and gallstone formation. Clin Chim. 2010 Nov; 411(21-22): 1625-31.

  10. Xu GQ, Xu CF, Chen HT, Liu S, Teng XD, Xu GY, et al. Association of caveolin-3 and cholecystokinin A receptor with cholesterol gallstone disease in mice. World. J. Gastroenterol. 2014 Jul; 20(28): 9513-8.

  11. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006 Jul; 368(9531): 230-9.

  12. Stokes CS & Lammert F. Transporters in cholelithiasis. Biol Chem. 2012 Jan; 393(1-2): 3-10.

  13. Hernández-Nazará A, Curiel-López F, Martínez-López E, Hernández-Nazará Z, Panduro A. Genetic predisposition of cholesterol gallstone disease. Ann Hepatol. 2006 Jul-Sep; 5(3): 140-9.

  14. Castro-Torres IG, Martínez-Vázquez M. Transportadores de lípidos biliares: una revisión actualizada. GEN. 2013 Ene-Mar; 67(1): 49-57.

  15. Hoda F & Green RM. Hepatic canalicular membrane transport of bile salt in C57L/J and AKR/J mice: implications for cholesterol gallstone formation. J Membr Biol. 2003 Nov; 196(1): 9-14.

  16. Kong FM, Sui CY, Li YJ, Guo KJ, Guo RX. Hepatobiliary membrane transporters involving in the formation of cholesterol calculus. Hepatobiliary Pancreat Dis Int. 2006 May; 5(2): 286-9.

  17. Kong J, Liu BB, Wu SD, Wang Y, Jiang QQ, Guo EL. Enhancement of interaction of BSEP and HAX-1 on the canalicular membrane of hepatocytes in a mouse model of cholesterol cholelithiasis. Int J Clin Exp Pathol. 2014 Mar; 7(4): 1644-50.

  18. Lammert F, Wang DQ, Hillebrandt S, Geier A, Fickert P, Trauner M, et al. Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis. Hepatology. 2004 Jan; 39(1): 117-28.

  19. Acalovschi M, Tirziu S, Chiorean E, Krawczyk M, Grünhage F, Lammert F. Common variants of ABCB4 and ABCB11 and plasma lipid levels: a study in sib pairs with gallstones, and controls. Lipids. 2009 Jun; 44(6): 521-6.

  20. Nakken KE, Labori KJ, Rødningen OK, Nakken S, Berge KE, Eiklid K, et al. ABCB4 sequence variations in young adults with cholesterol gallstone disease. Liver Int. 2009 May; 29(5): 743-7.

  21. Yamanashi Y, Takada T, Yoshikado T, Shoda J, Suzuki H. NPC2 regulates biliary cholesterol secretion via stimulation of ABCG5/G8-mediated cholesterol transport. Gastroenterology. 2011 May; 140(5): 1664-74.

  22. Pandey S. Genetic basis of gall stone disease. Hepatology. 2013 Oct; 58(4): 1519.

  23. Wittenburg H, Lyons MA, Li R, Kurtz U, Mössner J, Churchill, G.A., et al. Association of a lithogenic Abcg5/Abcg8 allele on chromosome 17 (Lith9 ) with cholesterol gallstone formation in PERA/EiJ mice. Mamm Genome. 2005 Jul; 16(7): 495-504.

  24. Acalovschi M, Ciocan A, Mostean O, Tirziu S, Chiorean E, Keppeler H, et al. Are plasma lipid levels related to ABCG5/ABCG8 polymorphisms? A preliminary study in siblings with gallstones. Eur J Intern Med. 2006 Nov; 17(7): 490-4.

  25. Von Kampen O, Buch S, Nothnagel M, Azocar L, Molina H, Brosch M, et al. Genetic and functional identification of the likely causative variant for cholesterol gallstone disease at the ABCG5/8 lithogenic locus. Hepatology. 2013 Jun; 57(6): 2407-17.

  26. Liu CL, Chang SJ, Chiang HJ. Quantitative analysis of cholesterol nucleation with time in supersaturated model bile. Chem Phys Lipids. 2011 Feb; 164(2): 125-30.

  27. Grebe A, Latz E. Cholesterol crystals and inflammation. Curr Rheumatol Rep. 2013 Mar; 15(3): 313.

  28. Chuang SC, His E, Lee KT. Mucin genes in gallstone disease. Clin Chim Acta. 2012. Oct; 413(19-20): 1466-71.

  29. Yang L, Chen JH, Cai D, Wang LY, Zha XL. Osteopontin and integrin are involved in cholesterol gallstone formation. Med Sci Monit. 2012 Jan; 18(1): BR16-23.

  30. Andrianifahanana M, Moniaux N, Batra SK. Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim. Biophys. Acta. 2006 Apr; 1765(2): 189-222.

  31. Chuang SC, His E, Wang SN, Yu ML, Lee KT, Juo SH. Polymorphism at the mucin-like protocadherin gene influences susceptibility to gallstone disease. Clin. Chim. Acta. 2011 Nov; 412(23-24): 2089-93.

  32. Koppisetti S, Jenigiri B, Terron MP, Tengatiini S, Tamura H, Flores LJ, et al. Reactive oxygen species and the hypomotility of the gall bladder as targets for the treatment of gallstones with melatonin: a review. Dig Dis Sci. 2008 Oct; 53(10): 2592-603.

  33. Micucci M, Ioan P, Aldini R, Cevenini, M, Alvisi V, Ruffilli C, et al. Castanea sativa Mill. extract contracts gallbladder and relaxes sphincter of Oddi in guinea pig: a natural approach to biliary tract motility disorders. J Med Food. 2014 Jul; 17(7): 795-803.

  34. Wang HH, Portincasa P, Liu M, Tso P, Samuelson LC, Wang DQ. Effect of gallbladder hypomotility on cholesterol crystallization and growth in CCK-deficient mice. Biochim Biophys Acta. 2009 Feb; 1801(2): 138-46.

  35. Nihei N, Sekime A, Miyasaka K, Kanai S, Takiguchi S, Funakoshi A. Administration of ursodeoxycholate failed to prevent sludge and/or gallstone formation in cholecystokinin-1(A) receptor-deficient mice. Biomed Res. 2011 Dec; 32(6): 401-6.

  36. Di Ciaula A, Wang DQ, Garruti G, Wang HH, Grattagliano I, de Bari O, et al. Therapeutic reflections in cholesterol homeostasis and gallstone disease: a review. Curr Med Chem. 2014 Apr; 21(12): 1435-47.

  37. Mohammadi A, Bazrafshani MR, Oshaghi EA. Effect of garlic extract on some serum biochemical parameters and expression of npc1l1, abca1, abcg5 and abcg8 genes in the intestine of hypercholesterolemic mice. Indian J Biochem Biophys. 2013 Dec; 50(6): 500-4.

  38. Castro-Torres IG & Bravo-Duarte GA. Proteínas de Niemann-Pick como objetivos terapéuticos moleculares para el tratamiento de cálculos biliares de colesterol. Revista Biomédica 2013 May-Ago; 24(2): 65-71.

  39. Stein A, Hermoni D, Elis A, Konikoff FM. Effect of ezetimibe on the prevalence of cholelithiasis. World J Gastroenterol 2012 Oct; 18(40): 5789-92.

  40. Navarro-Santamaría V, Zabala-Letona A, Gómez-Zorita S, Portillo-Baquedano, MP. Metabolismo del colesterol: bases actualizadas. Rev Esp Obes. 2009 Nov-Dic; 7(6): 360-384.

  41. Davis HR, Jr Altmann, SW. Niemann-Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter. Biochim. Biophys. Acta. 2009 Jul; 1791(7): 679-83.

  42. Park SW. Intestinal and hepatic niemann-pick c1-like 1. Diabetes Metab J. 2013 Aug; 37(4): 240-8.

  43. Morales MG, Amigo L, Balboa E, Acuña M, Castro J, Molina H, et al. Deficiency of Niemann-Pick C1 protein expression protects against diet-induced gallstone formation in mice. Liver Int. 2010 Jul; 30(6): 887-97.

  44. Jiang ZY, Jiang CY, Wang L, Wang JC, Zhang SD, Einarsson C, et al. Increased NPC1L1 and ACAT2 expression in the jejunal mucosa from Chinese gallstone patients. Biochem Biophys Res Commun 2009 Jan; 379(1): 49-54.

  45. Méndez-Sánchez N, Zamora-Valdés D, Flores-Rangel JA, Pérez-Sosa JA, Vásquez-Fernández F, Lezama-Mora JI, et al. Gallstones are associated with carotid atherosclerosis. Liver Int. 2008 Mar; 28(3): 402-6.

  46. Valasek MA, Repa JJ, Quan G, Dietschy JM, Turley SD. Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters. Am J Physiol Gastrointest Liver Physiol 2008 Oct; 295(4): G813-22.




2020     |     www.medigraphic.com